Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 11/20 | 0.48 |
| ▸ | EP300 | Q09472 | 2/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.44 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11617666 | 0.81 | CDK2 (0.36) | IDO1EP300KAT2BKAT8HDAC3 | |
| SCHEMBL11331686 | 0.81 | APP (0.52) | IDO1EP300KAT2BKAT8HDAC3 | |
| SCHEMBL1772088 | 0.77 | HSP90AA1 (0.53) | IDO1APPMAPTTDP1 | |
| SCHEMBL89098 | 0.76 | GABRA1 (0.46) | CYP1A2MAPTHPGDALOX15TSHR | |
| SCHEMBL1149420 | 0.73 | ALDH1A1 (0.50) | CYP1A2HPGDTSHRHSD17B10TDP1 | |
| SCHEMBL1683810 | 0.73 | ALDH1A1 (0.50) | CYP1A2HPGDTSHRHSD17B10TDP1 | |
| SCHEMBL666673 | 0.73 | DPP4 (0.33) | TSHR | |
| SCHEMBL11622368 | 0.71 | PTPN22 (0.46) | CYP1A2MAPTHSD17B10 | |
| SCHEMBL9716921 | 0.71 | IDO1 (0.62) | IDO1EP300KAT2BKAT8HDAC3 | |
| SCHEMBL9710951 | 0.70 | CASP6 (0.39) | LDHAMAPTHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112282-A1 | IDO INHIBITORS AND THERAPEUTIC USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. | 2011-05-12 | — | — | US | disclosed |
| WO-2009127669-A2 | IDO INHIBITORS AND THERAPEUTIC USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112282-A1 | IDO INHIBITORS AND THERAPEUTIC USES THEREOF | IDO1, IDO2, IDH3B | IDO1 1/4885EP300 1517/4885KAT2B 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.